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E-mail: gyannarelli@favaloro.edu.arExtracellular vesicles (EVs) play key roles in cell biology and
may provide new clinical diagnostics and therapies. However,
it has proven difficult to develop protocols for their purifica-
tion and characterization. One of the major barriers in the field
has been a lack of convenient assays for their bioactivity. Devel-
oping assays has not been a trivial matter, because of the
heterogeneity of EVs, the multiple activities they demonstrate,
and the uncertainty about their modes of action. Therefore, it is
likely that multiple assays for their activities are needed. One
important assay will be for the anti-inflammatory activity
observed in mice after administration of the small EVs
commonly referred to as exosomes. We developed an assay
for the anti-inflammatory activity of exosomes with a line of
mouse macrophages. The assay makes it possible to rank
different preparations of exosomes by their anti-inflammatory
activity, and their ranking predicts their efficacy in suppressing
LPS-stimulated inflammation in mice. The assay is convenient
for comparing multiple samples and, therefore, should be use-
ful in developing protocols for the purification and character-
ization of anti-inflammatory exosomes.
INTRODUCTION
Extracellular vesicles (EVs) have attracted attention because of their
roles in the biology of most organisms, ranging from some parasites
and bacteria to essentially all the cells in multicellular organisms.1–5
Also, EVs have been pursued as plasma markers of disease progres-
sion and for their potential as therapeutic agents.3,4 Special attention
has been paid to the very small EVs (30 to 200 nm in diameter) that
are referred to as exosomes and that appear to be derived from the
multivesicular bodies found in the endomembrane system ofmost eu-
karyotic cells.2 As a consequence of their origin, exosomes are highly
enriched in proteins involved in multivesicular endosome biogenesis
(e.g., Alix and Tsg101) and tetraspanin membrane proteins (e.g.,
CD63 and CD81), which are widely used as exosome biomarkers.6
As reflected in a series of reviews,7–10 research on EVs in general
and on exosomes in particular has met a number of technological
challenges. No consensus has emerged on the best protocol to isolate
and purify exosomes in spite of numerous attempts with classicalMolecular Therapy: Methods
This is an open access article under the CC BY-NCtechniques such as centrifugation, precipitation, size exclusion chro-
matography, ion exchange chromatography, and immuno-purifica-
tion. Similarly, no consensus on purification protocols has emerged
from the application of advanced techniques developed for synthetic
nanoparticles such as those based on hydrodynamic features com-
bined with other properties.8,10,11 Also, there is no consensus on
the compositions of the vesicles from the many reports and large
databases that have been developed.12 Instead, the data reveal marked
differences in the composition of similar EVs from different sources
or different culture conditions. In addition, the reports and databases
reveal thousands of proteins and other components that either co-
purify or adhere to the surfaces of vesicles. Among the problems
encountered is that there is no consensus as to how to count
exosomes, because their small size is below the sensitivity of tech-
niques for cell counting, and artifacts have been encountered in the
use of techniques such as light scattering or nanoparticle tracking
analysis.8–10
The technical challenges encountered with EVs, such as exosomes,
would obviously benefit from convenient assays for their bioactivity.
Unfortunately, few are available.13 A series of assays will probably be
required, because exosomes from different sources have demon-
strated to have multiple activities, including anti-inflammatory,
anti-immune, anti-coagulant, pro-angiogenic, and pro-tumorigenic.
Many of these activities were only demonstrated after injection of
the exosomes into mice that were models for human diseases.14–16
Assays in mouse models, however, are time consuming and costly
of mice and other materials, including exosomes. Also, if the& Clinical Development Vol. 13 June 2019 ª 2018 The Author(s). 67
-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Molecular Therapy: Methods & Clinical Developmentexosomes are produced by human cells, the mice must be housed in
facilities with special precautions to prevent the spread of human
pathogens. Therefore, assays in mice are impractical for the multiple
samples that must be assayed in a purification protocol.
One of the bioactivities observed with some exosome preparations
obtained from mesenchymal stromal cells (MSCs) was to suppress
inflammation in mouse models for traumatic brain injury17–19 and
status epilepticus.20 Exosomes that are anti-inflammatory are of
special interest as therapeutic agents, because inflammation is part
of the pathology of a broad range of diseases, including obesity,21
diabetes,22 myocardial infarction,23 and Alzheimer’s disease.24 Anti-
inflammatory exosomes may be particularly effective for treating
CNS diseases, since they cross the blood barrier that is not breached
effectively by any known drug.25,26 Recently, we developed an assay
with macrophages in vitro for the anti-inflammatory activity of
exosomes. The assaymade it possible to classify different preparations
of exosomes produced with the same protocol by their anti-
inflammatory activity. The classifications predicted the activity of
the exosomes in suppressing lipopolysaccharide (LPS)-induced
inflammation in mice.
RESULTS
Standardization of the Assay inMurine RAW264.7Macrophages
For the assay, we elected to use a cell line of mouse macrophages that
have been commonly used in assays for anti-inflammatory activity
and that can be used to generate a stable bank for repeated assays.
It has been well established that LPS stimulation polarizes macro-
phages toward the M1 phenotype, which is characterized by the
production of high levels of pro-inflammatory cytokines, such as
tumor necrosis factor alpha (TNF-a) and interleukin (IL)-6.27
Thus, the assay is able to determine the anti-inflammatory activity
of a molecule and/or compound based on its potency to inhibit the
acquisition of the M1 phenotype in LPS-stimulated macrophages.
For this purpose, we first standardized conditions for maximal recov-
ery of viable macrophages from frozen vials to create a bank. We then
found that the response to LPS varied with the plating density of the
cells and that the exosomes we tested were ineffective if the cells were
stimulated with doses higher than 10 ng/mL of LPS. Therefore, we
standardized the assay for plating density of macrophages and the
dose of purified LPS that stimulated the cells to a moderate level of
cytokine expression, as judged by ready suppression by dexametha-
sone (Figures 1 and S1). We then examined the time course of the
cytokine response to determine the optimal cytokine and the optimal
time for the assay. Unstimulated cells showed almost undetectable
levels of pro-inflammatory cytokines, indicating an uncommitted
macrophage phenotype (M0) (Figure 1). As expected, macrophages
responded to LPS by increased levels of mRNAs for TNF-a, IL-1b,
IL-6, and iNOS that were effectively suppressed by dexamethasone
(Figure 1B). The upregulation of these markers by LPS is in agreement
with the acquisition of the M1-proinflammatory phenotype. ELISAs
on medium confirmed increased secretion of TNF-a and IL-6 (Fig-
ure 1C). IL-1b was not detectable by ELISA, as LPS, per se, is not suf-
ficient to trigger caspase-1-dependent IL-1bmaturation and secretion68 Molecular Therapy: Methods & Clinical Development Vol. 13 June 20in murine macrophages.28 For convenience and simplicity, we
decided to use an ELISA for the readout of the in vitro macrophage
assay. Results indicated that the assays for IL-6 at 4 h showed the
optimal differences, considering that dexamethasone suppressed
IL-6 production by about 60% at this time point (Figure 1C). In
this experimental setting, containing only macrophages in culture,
the secretion of IL-6 specifically represents the LPS-induced M1
polarization of macrophages. Repeated assays confirmed that the dif-
ferences observed in the ELISAs for IL-6 at 4 h were reproducible
(Figure 1D), and these conditions were selected for the assay. There-
fore, we standardized the conditions for maximizing the recovery of
viable macrophages from frozen stocks and for the expansion, seed-
ing, and stimulation of the cells (Figure 2).
Preparation of Exosomes for Assay
To test the assay, we used seven independent samples of exosomes
prepared under the same protocol. In brief, we used bone
marrow-derived MSCs from a single donor, and the same prepa-
ration at a low density of passage 4 or 5.29 The MSCs were
expanded to about 70% confluency in medium containing fetal
bovine serum (FBS) and then conditioned in a chemically defined,
protein-free medium.18 The exosomes secreted into the condi-
tioned medium were concentrated and purified with an anion ex-
change column.
The size and number of the exosomes in the seven separate prepa-
rations were assessed by nanoparticle tracking analysis (NTA). To
ensure reproducibility of the NTA data, the settings on the instru-
ment were maintained as described in Materials and Methods. In
addition, the instrument was calibrated before each assay with a
stock solution of silica microspheres that were about the same
size (100-nm diameter) and about the same refractive index as
the exosomes.30 The mean and mode diameters of the seven prep-
arations ranged from 99 to 162 nm (Figure 3; Table 1). The same
assays suggested that the concentrations of exosomes varied from
13.1 to 51.2  109/mL. However, as is generally recognized,8,10 there
are limitations to data obtained on exosomes by NTA and all other
available procedures. The NTA profile of sizes (Figure 3) showed
that the nanoparticles in the samples were not homogeneous, as
indicated by the comparison to the profile of the microspheres.
The data for concentrations probably included nanoparticles of
cellular origin that were not exosomes, exosomes of varying sizes,
disrupted exosomes, or fused exosomes.31 Nevertheless, the diam-
eter of the nanoparticles included in the 90th percentile (D90),
when ranked from the smallest to largest, were below 200 nm for
most of the isolated samples (Table 1), implying that they contained
mainly exosomes. Furthermore, exosomes have a defined protein
signature according to recent proteomic data collected in the Exo-
Carta database.32 In this context, the isolated exosomes were
positive for human-specific CD63 and CD81, negative for 11 other
epitopes found on human MSCs,18 and positive for Tsg101 and Alix
(D.-k.K. and D.J.P., unpublished data). The identification of this
selective subset of proteins further supports the hypothesis that exo-
some samples were highly purified.19
Figure 1. Time Course Analysis of LPS-Stimulated Macrophages
(A) Diagram to depict the basic experimental design. Murine RAW 264.7 macrophage cells were seeded at a density of 1  105 cells per square centimeter and cultured for
20 h before stimulation with a dose of 10 ng/mL LPS with or without the addition of the anti-inflammatory corticosteroid dexamethasone (1 mg/mL). Cells and conditioned
media were assayed at 2, 4, and 6 h after stimulation. (B) qRT-PCR assay for the expression of TNF-a, IL-1b, IL-6, and iNOS. Individual PCR reactions were normalized
against the internal control GAPDH, and transcript levels in untreated macrophages were expressed as 1 U. Data represent mean ± SD of three independent experiments.
*p < 0.0001 between the LPS and LPS+Dexa groups derived from one-way ANOVA after multiple comparisons, Tukey post hoc test. (C) TNF-a and IL-6 secretion in
conditioned media assessed by ELISA. Data represent mean ± SD of an experiment run in quadruplicate. *p < 0.0001 between the LPS and LPS+Dexa groups derived from
one-way ANOVA after multiple comparisons, Tukey post hoc test. (D) Reproducibility of the IL-6 ELISA in conditioned media at 4 h post-LPS stimulation. Data represent
mean ± SD of eight independent experiments. *p < 0.0001 between the LPS and LPS+Dexa groups derived from one-way ANOVA after multiple comparisons, Tukey post
hoc test.
www.moleculartherapy.orgEfficacy of the Assay of the Anti-inflammatory Activity in Culture
Preliminary dose-response tests with five of the preparations indi-
cated that maximal effects in the assay were obtained with an exosome
dose of approximately 0.5  109 vesicles per milliliter (Figure S2). To
simplify the assay, this dose was used in further comparisons. The
effects of the LPS in converting unstimulated M0 cells to an
M1-like phenotype were apparent from visual inspection of the
cultures, in which the cells with rounded morphology of M0 macro-
phages flattened into a pancake-like morphology of M1 macrophages
(Figure 4A). Also, the effects of dexamethasone and the exosomes on
inhibiting the acquisition of the M1-like morphology were apparent.
For convenience, we expressed the results in terms of how much theMolecuexosomes reduced the LPS-stimulated levels of IL-6 (Figure 4B). The
results indicated that five of the seven preparations had about the
same anti-inflammatory activity. One (#1) was inactive. One (#3)
had more activity than any of the others and completely inhibited
the LPS-stimulated expression of IL-6; i.e., it was 100% effective on
the scale used in Figure 4B. These differences in the anti-inflamma-
tory activity of the preparations can be attributed to several factors,
but the stability of exosomes through the purification process and
storage conditions may be a critical aspect. A recent review article
summarized current strategies for EV preservation, which are
primarily based on data obtained by measuring particle numbers,
size, and aggregation.33 Unfortunately, little is known about thelar Therapy: Methods & Clinical Development Vol. 13 June 2019 69
Figure 2. In Vitro Macrophage Assay Design
Schema showing the different steps involved in the in vitro
macrophage assay. First, macrophages (2  106 cells)
were recovered from a frozen vial in 25 mL medium sup-
plemented with 10% FBS and antibiotics. After 24 h of
incubation at 37C in 5% CO2, the cells were detached by
gentle scraping with a cell scraper. Cells were counted and
seeded in triplicate at a density of 1  105 cells per square
centimeter in a volume of 300 mL DMEM containing 5% FBS
plus antibiotics. The stimulation was performed by replac-
ing the 300 mL culturing medium with a similar volume of
medium alone (5% FBS and antibiotics) or containing LPS
(10 ng/mL), LPS plus dexamethasone (1 mg/mL), or LPS
plus exosomes (0.5  109 vesicles per milliliter). The
supernatant was collected after 4 h of incubation at 37C
and kept frozen until interleukin determination by ELISA.
Molecular Therapy: Methods & Clinical Developmentbest conditions to preserve the biological activity of exosomes, mainly
because biological tests are lacking.
To better characterize the effect of exosomes in LPS-stimulated mac-
rophages, we also determined the mRNA expression of iNOS and
arginase-1 (Arg1) at 4 h. We found that exosomes significantly
decreased the upregulation of iNOS by 45% in LPS-stimulated cells
(1.00 ± 0.26 versus 0.55 ± 0.16 relative units; LPS versus LPS + exo-
somes, respectively, p < 0.009). The specific M2-macrophage marker
Arg1 was undetectable in our assay conditions. These results infer
that exosomes act by suppressing the polarization ofM0macrophages
toward the M1 phenotype by LPS stimulation.
The Assay as a Predictor of Anti-inflammatory Activity In Vivo
To assess the predictive efficacy of the assay, the same seven prepara-
tions were tested in mice in which a moderate degree of inflammation
was induced with LPS and the inflammatory response followed by
expression of IL-1b and IL-6 in spleen (Figure 5). These pro-inflam-
matory cytokines peaked at 2 h after LPS administration (Figure S3);
thus, this time point was used to test the anti-inflammatory potential
of the different exosome preparations. The intravenous (i.v.) infusion
of exosomes (about 5 109 vesicles per mouse) was more effective in70 Molecular Therapy: Methods & Clinical Development Vol. 13 June 2019suppressing the upregulation of IL-6 than IL-1b
in spleen (Figure 5), possibly because LPS-stimu-
lated levels were lower (Figure S3).
To determine the predictive potential of the
in vitro macrophage assay, we plotted the sup-
pression of IL-6 secretion in the macrophage
assay against the reduction of IL-1b and IL-6 in
the spleen of LPS-treated mice using data from
Figures 4B and 5B. The values for anti-inflamma-
tory activity (percentage of reduction in secreted
IL-6) from the in vitro assay correlated with the
suppression of mRNA levels in spleen for IL-6
(r2 = 0.861, p = 0.003) and for IL-1b (r2 =
0.812, p = 0.006) (Figure 6A). Furthermore, theassay also showed a positive correlation with the reduction of IL-1b
(r2 = 0.694, p = 0.020) and IL-6 (r2 = 0.811, p = 0.006) contents in
the spleen of mice receiving exosomes after LPS administration (Fig-
ure 6B). These data imply that IL-6 determination in the macrophage
assay may be useful for estimating the anti-inflammatory potential of
exosome preparations in vivo.
DISCUSSION
The in vitro assay described here can assess multiple samples of
exosomes for one of their important activities in vivo, the ability to
suppress inflammation both systemically and in the brain.18–20 There-
fore, the assay has many obvious potential applications. One is to
develop more rigorous protocols for the isolation and purification
of anti-inflammatory exosomes. Another is to identify the best condi-
tions for storage or transport without loss of activity. Still another is
the identification of active components in the exosomes by detailed
comparisons of those that have anti-inflammatory activity with those
that do not.
The purification and characterization of most biomaterials have
required convenient assays for either their structure or their
function. However, the stringency of the assays and criteria for
Figure 3. Isolation and Characterization of Different Preparations of Exosomes
(A) Schema of the procedure to isolate exosomes from MSC-conditioned media. Exosomes were collected in chemically defined protein-free media during 48 h and then
were concentrated and purified by using anion exchange chromatography. The elution fractions containing exosomes were pooled and dialyzed against PBS. (B) Char-
acterization of exosomes by nanoparticle tracking analysis (NTA). Representative size distribution profiles of the different exosome preparations used in this study. See Table
1 for concentration (particles per milliliter) and size (in nanometers) of exosome samples according to NTA measures.
www.moleculartherapy.orgpurification have, of necessity, decreased with the complexity of
the biomaterial, ranging from small molecules to proteins, and
to cells. The purity of most biologically important small molecules
can readily be defined by their atomic compositions and formulas
for chemical functions. The purity of proteins cannot be defined by
the same criteria. Instead, the goal is “homogeneity,” defined as re-
covery as a single component through multiple fractionation pro-
cedures. Cells present a higher order of complexity, and there is, as
yet, no way to define any of them in terms of their thousands of
components that can change in response to environmental cues.
Exosomes are simpler than cells, but serious challenges haveTable 1. Characteristics of the Different Exosome Preparations Used in This S
Exosome Preparation
NTA Analysis










aValues relative to level for sample #4. OD, optical density.
Molecubeen encountered in efforts to define them in terms of structure
and the few convenient assays available for their function.
In the past years, the potential application of exosomes as biomarkers
of disease and therapeutic agents has attracted a lot of research inter-
est.34 Recently, a bioassay to measure the plasmin generation capacity
of leukocyte-derived extracellular vesicles isolated from human
plasma demonstrated prognostic value in the survival of septic shock
patients.13 Here, we developed an in vitro assay that measures the
anti-inflammatory potential of MSC-derived exosomes based on
their ability to suppress the acquisition of the M1 phenotype intudy
Protein (mg/mL) CD63 (OD U/mL)a
ometers)
Mode D90
151.8 206.4 105 3.21
137.0 230.5 62 1.95
123.1 183.0 86 1.80
131.0 186.2 34 1.00
155.7 212.3 44 1.50
99.2 183.2 110 3.15
106.4 198.2 111 4.26
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Figure 4. Efficacy of the In Vitro Macrophage Assay to Test the Anti-inflammatory Activity of Exosomes
(A) Representative phase-contrast images showing changes in themorphologyof RAW264.7macrophages after stimulationwith LPSwith orwithout the concomitant addition of
exosomes (scale bar represents 100 mm). Inserts indicate a highermagnification image. (B) ELISA for IL-6 in conditionedmedia of LPS-stimulatedmacrophages. Seven exosome
preparations were tested for their anti-inflammatory activity using a dose of 0.5  109 vesicles per milliliter. Dexamethasone and active exosome preparations significantly
reduced IL-6 secretion. Results are expressed as percentage of change of IL-6 secretion in conditioned media relative to LPS-stimulated levels. Data represent mean ± SD of
three independent experiments. *p < 0.05; #p < 0.01; zp < 0.001, against the LPS group derived from one-way ANOVA after multiple comparisons, Tukey post hoc test.
Molecular Therapy: Methods & Clinical DevelopmentLPS-stimulated macrophages. The mechanisms mediating the anti-
inflammatory effect of exosomes are still unknown, but they are
more likely related to a complex combination of factors than to the
activity of a specific molecule or enzyme. Interestingly, we found
that the anti-inflammatory activity of exosomes in the in vitro assay
positively correlates with their activity in vivo. Hence, the most effec-
tive preparations in vitro showed the highest suppression of IL-1b and
IL-6 in the spleen of mice subjected to LPS-induced systemic inflam-
mation. The fact that macrophages are critical elements in the defense
against bacterial infections and the fact that both IL-1b and IL-6
secretion in spleen are mainly mediated by Toll-like receptor 4
(TLR4)-expressing monocytes and macrophages may explain the
positive correlation observed with the in vitro macrophage assay.
Whether the classification of different exosome preparations in terms
of their anti-inflammatory potential in vitro is also associated with the
therapeutic effect in other inflammatory diseases needs to be further
studied. In this context, the in vitro assay developed here is similar to
assays used extensively in the past to screen for drugs that suppress
inflammation.35 It shares with them many of the same limitations,
such as the inability to simulate fully the complex inflammatory re-
sponses seen in vivo. The assay also has several specific limitations.
One is the difficulty of ensuring that the same numbers of exosomes
are assayed in comparing different samples, given the current limita-
tions of assaying exosomes.8,10 Another limitation is that it was diffi-
cult in the assay to establish the usual pharmacological criterion of an
effective dose for a 50% response. Still another limitation is the need
to standardize a bank of macrophages, their response to LPS, and then
their response to exosomes. The initial efforts are by trial and error, in
part because the mode of action of exosomes on macrophages is still
unknown. Once standardized, however, the assay is reproducible and,
as illustrated here, predicts some of the effects of anti-inflammatory
exosomes in vivo.72 Molecular Therapy: Methods & Clinical Development Vol. 13 June 20MATERIALS AND METHODS
Reagents and Cell Culture
High-glucose DMEM with GlutaMAX Supplement and sodium
pyruvate, alpha-minimum essential medium (MEM) eagle medium,
L-glutamine, and the antibiotics (penicillin-streptomycin) were ob-
tained from GIBCO (Life Technologies, Rockville, MD, USA). FBS
and LPS from Escherichia coli serotype 0111:B4 (Sigma, L4391)
were purchased from Atlanta Biologicals (Lawrenceville, GA, USA)
and Sigma (St. Louis, MO, USA), respectively. Dexamethasone was
from Spectrum Chemicals (Gardena, CA, USA). Chemically defined
Chinese hamster ovary (CHO) medium (CD-CHO Medium; catalog
#10743-002), HT Supplement, MEM Vitamin Solution, MEM Non-
Essential Amino Acids solution, PBS (pH 7.4), Trypan Blue (0.4%),
and Trypsin-EDTA (0.25%/1 mM) were obtained from Invitrogen
(Carlsbad, CA, USA). D-(+)-glucose was from Sigma (St. Louis,
MO, USA). Tissue culture flasks (75 cm2), 5-STACK multi-layer
chambers (CellSTACK, 5 layers, 3,180-cm2 cell growth area), and
15-cm and 48-well tissue culture-treated plates were from Corning
(Corning, NY, USA). Mouse TNF-a, IL-1b, and IL-6 DuoSet ELISA
kits were purchased from R&D Systems (Minneapolis, MN, USA).
Bradford reagent was purchased from Bio-Rad (Hercules, CA, USA).
Cells
RAW 264.7 cells, a murine macrophage-like cell line, were acquired
from the American Type Culture Collection (ATCC; Manassas,
VA, USA) and were cultured in DMEM supplemented with 5%
(v/v) FBS, 100 U/mL penicillin, and 100 mg/mL streptomycin at
37C in 5% CO2. Human MSCs were obtained from normal, healthy
donors with informed consent under procedures approved by the
Scott & White and Texas A&M institutional review boards (Center
for Distribution; https://medicine.tamhsc.edu/centers/irm/index.
html). MSCs were cultured as reported previously.1819
Figure 5. Anti-inflammatory Effects of Exosomes in a
Mouse Model of LPS-Induced Acute Systemic
Inflammation
(A) Schematic diagram of the experimental study design.
Mice were separated into different groups receiving PBS,
LPS (2.5 mg/kg), or LPS and exosomes (5 109 vesicles per
mouse). The same seven independent exosome prepara-
tions tested in the macrophage assay were evaluated in vivo.
The anti-inflammatory effect of the exosomes was deter-
mined by assessing their potential to inhibit the upregulation
of IL-1b and IL-6 in spleen samples collected after 2 h of LPS
administration. (B) qRT-PCR assay for the expression of
IL-1b and IL-6 in spleen samples. PCR reactions were
normalized using GAPDH, and transcript levels in LPS-
treated mice were expressed as 1 U. Dots represent indi-
vidual mice, and the lines represent the mean and SD. *p <
0.05; #p < 0.01; zp < 0.001, between LPS and LPS + exo-
some groups derived from one-way ANOVA after multiple
comparisons, Tukey post hoc test. (C) Quantitation of the
pro-inflammatory cytokines IL-1b and IL-6 in spleen samples
by ELISA. Results are expressed as relative units taking
cytokine levels in LPS-treated mice as 1 U. Dots represent
individual mice, and the lines represent the mean and SD.
*p < 0.05; #p < 0.01; zp < 0.001, between LPS and LPS +
exosome groups derived from one-way ANOVA after multiple
comparisons, Tukey post hoc test.
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Human MSC-derived exosomes were produced and purified as
described previously.18 Briefly, MSCs (500 cells per square centi-
meter) were plated in 15-cm-diameter tissue culture plates or
5-STACK multi-layer chambers in complete culture medium
(CCM). After 4–6 days (70% confluence cells), the medium was
removed, the cell layer was washed, and the cells were cultured in a
chemically defined protein-free medium that consisted of CD-
CHO Medium supplemented with L-glutamine, HT Supplement,
D-[+]-glucose, non-essential amino acids, and vitamins.18 After 6 h,
the medium was changed, the conditioned medium recovered from
6 to 48 h was centrifuged to remove cellular debris at 17,000  g
for 10 min at room temperature, and the supernatant was stored at
80C or used directly to isolate the exosomes. For the isolation of
exosomes, the conditioned medium was applied directly at room
temperature to a column containing the anion exchange resin (Q
Sepharose Fast Flow, GE Healthcare, Chicago, IL, USA) that had
been equilibrated with 50 mM NaCl in 50 mM phosphate bufferMolecular Therapy: Metho(pH 7.5). The column resin was washed with
100 mM NaCl in 50 mM phosphate buffer (pH
7.5) and then eluted with 500 mM NaCl in
50 mM phosphate buffer (pH 7.5). Exosome frac-
tions (20–30 mL) were pooled, dialyzed against
PBS (molecular weight cut-off [MWCO] of
300 kDa), and stored at 20C.
Nanoparticle Tracking Analysis
The concentration and size distribution of isolated
exosomes were measured with a NanoSight LM14instrument (Malvern Instruments, Malvern, UK). Data were analyzed
with Nanoparticle Tracking Analysis (NTA) software (v.3.2). The
analysis settings were optimized and kept constant between samples.
Readings were taken in triplicate by capturing video during 45 s at
30 frames per second (fps), at a camera level set to 13. Silica micro-
spheres were used as a size standard (100 nm, Polysciences). Purified
exosome samples were diluted 25–50 times with sterile and filtered
PBS yielding particle concentrations in the region of 0.5–1.5  109
particles per milliliter in accordance with the manufacturer’s
recommendations.
In Vitro Macrophage Assay
Frozen cells (2 106 cells per vial) were washed in 10mL previously
warm (37C) DMEM supplemented with FBS (10%) and antibiotics
(100 U/mL penicillin and 100 mg/mL streptomycin). Cells were
centrifuged at 450  g during 10 min, resuspended in 1 mL medium,
and cultured in a T75 flask containing 25 mL of the same medium for
24 h at 37C in 5% CO2. For the macrophage assay, cells wereds & Clinical Development Vol. 13 June 2019 73
Figure 6. Correlation between the Anti-inflammatory Activity of Exosomes
in the In Vitro Macrophage Assay and in the Mouse Model of LPS-Induced
Inflammation
(A) Correlation of the reduction in secreted IL-6 in the macrophage assay with the
reduction of IL-1b or IL-6 mRNA expression in the spleen of LPS-treated mice. (B)
Correlation of the reduction in secreted IL-6 in the macrophage assay with the
reduction of IL-1b or IL-6 in the spleen of LPS-treated mice. Pearson coefficient of
determination (r2) and the value of probability, p, are shown for each analysis.
Molecular Therapy: Methods & Clinical Developmentdetached by gentle scraping with a cell scraper, and they were
collected, centrifuged (10 min at 450  g), and resuspended in
DMEM containing 5% of FBS and antibiotics. After that, cells were
counted and seeded at a density of 1 105 cells per square centimeter74 Molecular Therapy: Methods & Clinical Development Vol. 13 June 20using 300 mL medium (5% of FBS plus antibiotics) per well in a
48-well plate. After 20 h of incubation, the macrophages were stimu-
lated by replacing the 300 mL culturing mediumwith a similar volume
of medium alone (5% FBS and antibiotics) or containing LPS
(10 ng/mL), LPS plus dexamethasone (1 mg/mL), or LPS in combina-
tion with exosomes (0.5 109 vesicles per milliliter). All the different
conditions were prepared in a total volume of 1 mL and tested in trip-
licates. In all cases, the dose of exosomes was loaded using a volume
that was not higher than 10% of the total volume. The conditioned
medium was collected after 4 h of incubation at 37C and kept frozen
until assayed for cytokines by ELISA.
LPS Mouse Model
All animal protocols were approved by the Texas A&M Animal Care
and Use Committee. Male BALB/c mice (10–12 weeks old) were used
for the experiments. We used a mouse model of endotoxemia that
consists of an i.v. injection of LPS. Vasodilation was achieved by
immersing the tail into warm water for 1 min. For i.v. administration,
LPS (2.5 mg/kg) was injected via tail vein using a 28G needle in a total
volume of 250 mL, either alone or in combination with exosomes
(approximately 5  109 vesicles). Control mice were injected with
saline. Mice were euthanized at 2 h after injection, and the spleens
were aseptically removed, snap frozen, and stored at 80C until
use. A preliminary experiment using 12 mice was carried out to deter-
mine the best time point (0, 2, or 6 h) for the detection of IL-1b and
IL-6 in spleen samples (Figure S3).
qRT-PCR Analysis
Total RNA was extracted from cells or tissue samples using TRIzol
reagent (Invitrogen, Carlsbad, CA, USA) as described by the manu-
facturer. One microgram of RNA was reverse-transcribed into
cDNA using random primers and MultiScribe reverse transcriptase
(High-Capacity cDNA Reverse Transcription Kit; Applied Bio-
systems, Foster City, CA, USA). qRT-PCR was performed by using
TaqManGene Expression Assays for genes of interest (Thermo Fisher
Scientific) (Table S1). Samples were assayed in triplicate using the
TaqMan Fast Advanced Master Mix on an Applied Biosystems
Sequence Detection System (SDS7900HT) with the following
conditions: 1 cycle for 2 min at 95C and 40 cycles at 95C for 1 s
and 60C for 20 s. Results were analyzed using the relative quantifica-
tion (2DDCt) method by normalizing the threshold cycle (Ct) values
against the reference gene glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH).36
Quantitation of TNF-a, IL-1b, and IL-6 by ELISA
Conditioned media from the macrophage assays were analyzed for
TNF-a, IL-1b, and IL-6 by ELISA following the manufacturer’s
recommendations (R&D Systems). Spleen samples were homoge-
nized in ice-cold 50 mM potassium phosphate buffer (pH 7.4)
containing 0.1% Triton X-100 and protease inhibitors (cOmplete
Protease Inhibitor Cocktail, Roche). Homogenates were clarified by
centrifugation (15 min at 10,000  g) and stored at 80C until
use. Samples were diluted in PBS (1 mg protein per milliliter) and
assayed for IL-1b and IL-6 by ELISA following the manufacturer’s19
www.moleculartherapy.orgrecommendations (R&D Systems). Protein concentrations were
determined using the Bradford micromethod assay (Bio-Rad).
Statistical Analysis
Continuous variables were expressed as mean ± SD. One-way
ANOVA with post hoc Tukey’s test was used for intergroup compar-
isons. The correlation between the anti-inflammatory activity
observed in the in vitro macrophage assay and in the LPS mouse
model was calculated by the Pearson coefficient of determination
(r2) and the p value. A value of p < 0.05 was considered statistically
significant.
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